How Prescription Digital Therapeutics Can Help Solve the Nation’s Diabetes Epidemic
Dr. Mark Berman, Chief Medical Officer of Better Therapeutics discusses how prescription digital therapeutics (PDTs) could reimagine how we treat type 2 diabetes and how our current system of treatment doesn’t work for more than half of patients. While standard of care focuses on treating symptoms, PDTs can enable physicians to focus treatment on behaviors that lead to the disease of type 2 diabetes. He talks about the company’s type 2 diabetes PDT candidate BT-001 and its recent positive primary endpoint data readout, physicians’ support of BT-001 to date, and its pathway to De Novo clearance.
Dr. Mark Berman serves as Better’s Chief Medical Officer. Previously, he practiced as an internal and lifestyle medicine physician at One Medical. Dr. Berman received his M.D. from Yale. He completed residency at Harvard’s Brigham and Women’s Hospital and a clinical research fellowship at University of California, San Francisco. He has also served as a director of the American College of Lifestyle Medicine.
0 Comments